Intelligence feed

What's new in the research

New studies, trial changes and FDA actions — each one opened, checked and written up by a person before it appears here, with a link to the original.

Follow compounds for a live feed →

Everything Studies Clinical trials FDA & regulatory Showing Epitalon only · clear ✕

July 2026

Advisory vote· 2026-07-24Epitalon Semax DSIP
Advisers back Epitalon and Semax, but not DSIP
Same story: these are recommendations, not approvals. None of these peptides is an approved medicine.
What this doesn't mean: A 'yes' vote is not approval and does not yet permit compounding; a 'no' vote is not a safety finding against a substance.
Primary source: FDA meeting page and agenda (no vote results posted) ↗Checked 2026-11-03

April 2026

Compounding list· 2026-04-15BPC-157 LL-37 Dihexa DSIP+8
FDA takes 12 peptides off its “do not compound” list
Taking them off that list doesn’t approve them or let pharmacies make them yet — it moves them into review.
What this doesn't mean: Removal from Category 2 does not make a substance eligible for compounding, and it is not FDA approval.
Primary source: FDA Category 2 list, nominations withdrawn (current as of 22 Apr 2026) ↗Checked 2026-11-03

How this feed works: candidates are gathered automatically from PubMed, ClinicalTrials.gov and FDA press releases. A person opens each one, writes the headline in plain English and approves it; the database won't let anything publish without that step. Methodology

What's new in the research

July 2026

Advisers back Epitalon and Semax, but not DSIP

April 2026

FDA takes 12 peptides off its “do not compound” list

July 2026

Advisers back Epitalon and Semax, but not DSIP

April 2026

FDA takes 12 peptides off its “do not compound” list